臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

About TAIR
	About TAIR

Browse By
	Institution
	Author
	Title
	Date
	Statistics Chart
	Institution Facts
	Trend

News
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

Copyright
	Publisher & Journal Policy
	TAIR Copyright Conference Minutes

Related Links
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"hsu c h"

Return to Browse by Author
Sorting by Title	Sort by Date

Showing items 281-305 of 1656 (67 Page(s) Totally)
<< < 7 8 9 10 11 12 13 14 15 16 > >>
View [10|25|50] records per page

Institution	Date	Title	Author
臺大學術典藏	2021-09-01T01:54:06Z	High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy	Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Shen Y.-C.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:54:06Z	Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil	Hsu C.-Y.; Shen Y.-C.; Yu C.-W.; Hsu C.; Hu F.-C.; Hsu C.-H.; Chen B.-B.; Wei S.-Y.; ANN-LII CHENG; Shih T.T.-F.
臺大學術典藏	2021-09-01T01:54:05Z	Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study	Ch'Ang H.-J.; Lin Y.-L.; Wang H.-P.; Chiu Y.-F.; Chang M.-C.; Hsu C.-H.; Tien Y.-W.; Chen J.-S.; Hsieh R.-K.; Lin P.-W.; Shan Y.-S.; ANN-LII CHENG; Chang J.-Y.; Whang-Peng J.; Hwang T.-L.; Chen L.-T.
臺大學術典藏	2021-09-01T01:54:05Z	Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials	Yang S.-H.; Kuo Y.-H.; Tien Y.-W.; Hsu C.; Hsu C.-H.; Kuo S.-H.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:54:04Z	T(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement	Kuo S.-H.; ANN-LII CHENG; Lin C.-W.; Hsu C.-H.; Wu M.-S.; Yeh K.-H.; Tzeng Y.-S.; Chen L.-T.
臺大學術典藏	2021-09-01T01:54:02Z	Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma	Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:53:58Z	Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy	Shao Y.-Y.; Huang C.-C.; Lin S.-D.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:53:58Z	Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma	Shau W.-Y.; Shao Y.-Y.; Yeh Y.-C.; Lin Z.-Z.; Kuo R.; Hsu C.-H.; Hsu C.; ANN-LII CHENG; Lai M.-S.
臺大學術典藏	2021-09-01T01:53:57Z	Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer	Lu L.-C.; Shao Y.-Y.; Hsu C.-H.; Hsu C.; Cheng W.-F.; Lin Y.-L.; ANN-LII CHENG; Yeh K.-H.
臺大學術典藏	2021-09-01T01:53:56Z	Dissimilar immunohistochemical expression of ERK and AKT between paired biopsy and hepatectomy tissues of hepatocellular carcinoma	Shao Y.-Y.; Chen C.-L.; Ho M.-C.; Huang C.-C.; Tu H.-C.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:53:55Z	Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems	Shao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:53:53Z	The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma	Shao Y.-Y.; Chang Y.-L.; Huang C.-Y.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:53:49Z	Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma	Lu L.-C.; Shao Y.-Y.; Kuo R.N.C.; Lin Z.-Z.; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; ANN-LII CHENG; Lai M.-S.
臺大學術典藏	2021-09-01T01:53:47Z	Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study	Hsu C.-H.; Kang Y.K.; Yang T.-S.; Shun C.-T.; Shao Y.-Y.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Hsu C.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:53:46Z	Nuclear expression of glioma-associated oncogene homolog 1 and nuclear factor-κb is associated with a poor prognosis of pancreatic cancer	Yang S.-H.; Hsu C.-H.; Lee J.-C.; Tien Y.-W.; Kuo S.-H.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:53:45Z	A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy	Shao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; ANN-LII CHENG; Lin Z.-Z.
臺大學術典藏	2021-09-01T01:53:45Z	Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy	Chen W.-W.; Lin C.-C.; Huang T.-C.; ANN-LII CHENG; Yeh K.-H.; Hsu C.-H.
臺大學術典藏	2021-09-01T01:53:44Z	Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study	Johnson P.J.; Qin S.; Park J.-W.; Poon R.T.P.; Raoul J.-L.; Philip P.A.; Hsu C.-H.; Hu T.-H.; Heo J.; Xu J.; Lu L.; Chao Y.; Boucher E.; Han K.-H.; Paik S.-W.; Robles-Avi?a J.; Kudo M.; Yan L.; Sobhonslidsuk A.; Komov D.; Decaens T.; Tak W.-Y.; Jeng L.-B.; Liu D.; Ezzeddine R.; Walters I.; ANN-LII CHENG
臺大學術典藏	2021-09-01T01:53:43Z	Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size	Lin Z.-Z.; Shau W.-Y.; Hsu C.; Shao Y.-Y.; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; ANN-LII CHENG; Lai M.-S.
臺大學術典藏	2021-09-01T01:53:42Z	Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy	Lu L.-C.; Shao Y.-Y.; Chan S.-Y.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:42:28Z	�]-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma	Lu L.-C.; Shao Y.-Y.; Lee Y.-H.; Hsieh M.-S.; Hsiao C.-H.; Lin H.-H.; Kao H.-F.; Ma Y.-Y.; Yen F.-C.; ANN-LII CHENG; Hsu C.-H.
臺大學術典藏	2021-08-31T06:42:27Z	Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases	Shao Y.-Y.; Ho M.-C.; ANN-LII CHENG; Hsu C.-H.
臺大學術典藏	2021-08-31T06:42:23Z	Clinical activity of metronomic chemotherapy in liver cancers	Shao Y.-Y.; ANN-LII CHENG; Hsu C.-H.
臺大學術典藏	2021-08-31T06:42:23Z	Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy	Shao Y.-Y.; Wu C.-H.; Lu L.-C.; Chan S.-Y.; Ma Y.-Y.; Yen F.-C.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:42:22Z	A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies	Lin C.-C.; Su W.-C.; Yen C.-J.; Hsu C.-H.; Su W.-P.; Yeh K.-H.; Lu Y.-S.; ANN-LII CHENG; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H.

Showing items 281-305 of 1656 (67 Page(s) Totally)
<< < 7 8 9 10 11 12 13 14 15 16 > >>
View [10|25|50] records per page

	English \| 正體中文 \| 简体中文 \| Total items :0
	Visitors : 52613931 Online Users : 862 Project Commissioned by the Ministry of Education Project Executed by National Taiwan University Library